Publications

  1. Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. Am J Hematol. 2020 Jan; 95 (1):4-9 Epub 2019 Oct 29
    View PubMed
  2. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88(L265P) Mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Am J Hematol. 2019 Dec 8 Epub 2019 Dec 08
    View PubMed
  3. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leuk Lymphoma. 2019 Dec; 60 (12):2960-2967 Epub 2019 May 16
    View PubMed
  4. Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019 Dec; 187 (5):588-594 Epub 2019 July 12
    View PubMed
  5. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2019 Nov 22 [Epub ahead of print]
    View PubMed
  6. Goyal G, Tella SH, Funni S, Kommalapati A, Inselman JW, Shah ND, Go RS, Ansell SM. Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer. 2019 Nov 12 [Epub ahead of print]
    View PubMed
  7. Karaca-Mandic P, Chang J, Go R, Schondelmeyer S, Weisdorf D, Jeffery MM. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage. Health Aff (Millwood). 2019 Nov; 38 (11):1887-1892
    View PubMed
  8. Durani U, Asante D, Halfdanarson T, Heien HC, Sangaralingham L, Thompson CA, Peethambaram P, Quevedo FJ, Go RS. Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population. J Natl Compr Canc Netw. 2019 Nov 1; 17 (11):1355-1361
    View PubMed
  9. Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, Patnaik MM, Rech KL, Go RS, Mayo Clinic Hisiocytosis Working Group. Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica. 2019 Oct 17 [Epub ahead of print]
    View PubMed
  10. Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J. Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer. 2019 Oct 15; 125 (20):3574-3581 Epub 2019 June 28
    View PubMed
  11. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clin Lymphoma Myeloma Leuk. 2019 Oct 9 Epub 2019 Oct 09
    View PubMed
  12. Sridharan M, Hook CC, Leung N, Winters JL, Go RS, Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Postsurgical thrombotic microangiopathy: Case series and review of the literature. Eur J Haematol. 2019 Oct; 103 (4):307-318 Epub 2019 July 23
    View PubMed
  13. Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019 Oct; 94 (10):2054-2071 Epub 2019 Aug 28
    View PubMed
  14. Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2019 Sep 23; 1-4 Epub 2019 Sept 23
    View PubMed
  15. Rayes HA, Vallabhajosyula S, Barsness GW, Anavekar NS, Go RS, Patnaik MS, Kashani KB, Jentzer JC. Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. Clin Res Cardiol. 2019 Sep 18 Epub 2019 Sept 18
    View PubMed
  16. Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S. Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 Aug 30 [Epub ahead of print]
    View PubMed
  17. Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2019 Aug 29 [Epub ahead of print]
    View PubMed
  18. Yadav S, Xie H, Bin-Riaz I, Sharma P, Bin-Riaz I, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug; 45 (8):1432-1438 Epub 2019 Mar 21
    View PubMed
  19. Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, Begna KH, Elliott MA, Hogan WJ, Tefferi A, Litzow MR, Go RS. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clin Proc. 2019 Aug; 94 (8):1467-1474
    View PubMed
  20. Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS. Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clin Proc. 2019 Aug; 94 (8):1542-1550
    View PubMed
  21. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019 Jul 9; 3 (13):1930-1938
    View PubMed
  22. Tella SH, Kommalapati A, Rech KL, Go RS, Goyal G. Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019 Jul; 19 (7):441-446 Epub 2019 Apr 01
    View PubMed
  23. Alkhouli M, Farooq A, Go RS, Balla S, Berzingi C. Cardiac prostheses-related hemolytic anemia. Clin Cardiol. 2019 Jul; 42 (7):692-700 Epub 2019 May 06
    View PubMed
  24. Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol. 2019 Jul; 94 (7):751-756 Epub 2019 Apr 30
    View PubMed
  25. Kobic A, Shah KK, Schmitt AR, Goyal G, Go RS, Guo R, Rech KL, Sartori-Valinotti JC, Mayo Clinic Histiocytosis Working Group. Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. Br J Dermatol. 2019 May 23 [Epub ahead of print]
    View PubMed
  26. Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Helias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J. Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2019 May 23 [Epub ahead of print]
    View PubMed
  27. Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019 May; 33 (5):1268-1272 Epub 2019 Feb 08
    View PubMed
  28. Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019 May; 33 (5):1273-1277 Epub 2019 Feb 20
    View PubMed
  29. Chen D, Goyal G, Go RS, Parikh SA, Ngufor CG. Improved Interpretability of Machine Learning Model Using Unsupervised Clustering: Predicting Time to First Treatment in Chronic Lymphocytic Leukemia. JCO Clin Cancer Inform. 2019 May; 3:1-11
    View PubMed
  30. Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Adv. 2019 Apr 23; 3 (8):1226-1229
    View PubMed
  31. Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2019 Apr 19 [Epub ahead of print]
    View PubMed
  32. Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, Go RS, Mayo Clinic Histiocytosis Working Group. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood 2019 Apr 4; 133 (14):1607-1610 Epub 2019 Jan 29
    View PubMed
  33. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):254-260 Epub 2019 Feb 15
    View PubMed
  34. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019 Apr; 94 (4):424-430 Epub 2019 Jan 08
    View PubMed
  35. Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019 Mar 12; 3 (5):744-750
    View PubMed
  36. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019 Mar 7; 9 (3):32 Epub 2019 Mar 07
    View PubMed
  37. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  38. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019 Mar; 33 (3):790-794 Epub 2018 Oct 12
    View PubMed
  39. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 2019 Mar; 33 (3):730-738 Epub 2018 Oct 15
    View PubMed
  40. Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clin Proc. 2019 Mar; 94 (3):472-483 Epub 2019 Feb 13
    View PubMed
  41. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. Am J Hematol. 2019 Mar; 94 (3):306-311 Epub 2018 Dec 13
    View PubMed
  42. Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Comparative analysis of staging systems in AL amyloidosis. Leukemia 2019 Mar; 33 (3):811-814 Epub 2019 Jan 23
    View PubMed
  43. Kommalapati A, Tella SH, Go RS, Goyal G. Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leuk Lymphoma 2019 Feb; 60 (2):553-555 Epub 2018 July 22
    View PubMed
  44. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. 2019 Feb; 33 (2):527-531 Epub 2018 Sept 26
    View PubMed
  45. Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019 Jan; 24 (1):96-102 Epub 2018 Nov 09
    View PubMed
  46. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid. 2019; 26 (sup1):101-102
    View PubMed
  47. Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018 Dec 11; 8 (12):125
    View PubMed
  48. Durani U, Go RS. In Reply. Oncologist 2018 Dec; 23 (12):e163 Epub 2018 July 16
    View PubMed
  49. Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018 Dec; 93 (12):1518-1523 Epub 2018 Oct 02
    View PubMed
  50. Villatoro-Villar M, Bold MS, Warrington KJ, Crowson CS, Goyal G, Shah M, Go RS, Koster MJ. Arterial involvement in Erdheim-Chester disease: A retrospective cohort study. Medicine (Baltimore). 2018 Dec; 97 (49):e13452
    View PubMed
  51. Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018 Nov 27; 2 (22):3149-3154
    View PubMed
  52. Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018 Nov 15; 8 (12):116
    View PubMed
  53. Neff JL, Rangan A, Jevremovic D, Nguyen PL, Chiu A, Go RS, Chen D, Morice WG, Shi M, Shi M. Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. Hum Pathol. 2018 Nov; 81:96-104 Epub 2018 June 24
    View PubMed
  54. Nalluru SS, Sridharan M, Go RS, Said S, Marshall AL. Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy. Am J Med Sci. 2018 Nov; 356 (5):492-498 Epub 2018 June 05
    View PubMed
  55. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02
    View PubMed
  56. Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Am J Hematol. 2018 Oct; 93 (10):1207-1210 Epub 2018 Aug 15
    View PubMed
  57. Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods. 2018 Oct; 461:15-22 Epub 2018 July 19
    View PubMed
  58. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018 Oct; 32 (10):2240-2249 Epub 2018 Feb 20
    View PubMed
  59. Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc. 2018 Oct; 93 (10):1351-1362
    View PubMed
  60. Durani U, Go RS, Kay NE. Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review. Clin Adv Hematol Oncol. 2018 Oct; 16 (10):670-676
    View PubMed
  61. Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK. Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Rev. 2018 Sep; 32 (5):361-367 Epub 2018 Mar 05
    View PubMed
  62. Duma N, Azam T, Riaz IB, Gonzalez-Velez M, Ailawadhi S, Go R. Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist. 2018 Sep; 23 (9):1076-1078 Epub 2018 Apr 26
    View PubMed
  63. Goyal G, Kommalapati A, Bartley AC, Gunderson TM, Adjei AA, Go RS. Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer. 2018 Aug; 122:214-219 Epub 2018 June 19
    View PubMed
  64. Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018 Aug; 32 (8):1811-1815 Epub 2018 Jan 30
    View PubMed
  65. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03
    View PubMed
  66. Ravindran A, Goyal G, Failing JJ, Go RS, Rech KL. Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. Clin Case Rep. 2018 Aug; 6 (8):1637-1638 Epub 2018 June 22
    View PubMed
  67. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30; 8 (8):70 Epub 2018 July 30
    View PubMed
  68. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol. 2018 Jul; 93 (7):889-894
    View PubMed
  69. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018 Jun 12; 8 (6):59 Epub 2018 June 12
    View PubMed
  70. Ravindran A, Go RS, Reichard KK, Marshall AL. Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center. Blood Res. 2018 Jun; 53 (2):166-167 Epub 2018 June 25
    View PubMed
  71. Goyal G, Bartley AC, Funni S, Inselman J, Shah ND, Marshall AL, Ashrani AA, Kapoor P, Durani U, Hashmi SK, Siddiqui MA, Buadi FK, Go RS, Kyle RA, Kumar S, Gonsalves WI. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia. 2018 Jun; 32 (6):1414-1420 Epub 2018 Mar 21
    View PubMed
  72. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. 2018 Jun; 32 (6):1421-1426 Epub 2018 Feb 21
    View PubMed
  73. Young JR, Johnson GB, Murphy RC, Go RS, Broski SM. (18)F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. J Nucl Med. 2018 May; 59 (5):774-779 Epub 2017 Nov 02
    View PubMed
  74. Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circ Cardiovasc Imaging. 2018 May; 11 (5):e006588
    View PubMed
  75. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018 Mar; 32 (3):729-735 Epub 2017 Sept 18
    View PubMed
  76. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
  77. Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND. Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. Haematologica 2018 Mar; 103 (3):e123-e125 Epub 2017 Dec 21
    View PubMed
  78. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Hogan WJ, Kumar SK. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplant. 2018 Mar; 53 (3):326-333 Epub 2017 Dec 21
    View PubMed
  79. Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol. 2018 Feb 20; 36 (6):600-608 Epub 2018 Jan 12
    View PubMed
  80. Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018 Feb; 93 (2):179-186 Epub 2017 Nov 10
    View PubMed
  81. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17
    View PubMed
  82. Parks NE, Goyal G, Go RS, Mandrekar J, Tobin WO. Neuroradiologic manifestations of Erdheim-Chester disease. Neurol Clin Pract. 2018 Feb; 8 (1):15-20
    View PubMed
  83. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018 Jan 11; 131 (2):163-173 Epub 2017 Nov 28
    View PubMed
  84. Kommalapati A, Tella SH, Durkin M, Go RS, Goyal G. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood 2018 Jan 11; 131 (2):265-268 Epub 2017 Nov 28
    View PubMed
  85. Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of t(11;14) multiple myeloma. Leukemia. 2018 Jan; 32 (1):131-138 Epub 2017 June 27
    View PubMed
  86. Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Kumar SK. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). Am J Hematol. 2018 Jan; 93 (1):17-22 Epub 2017 Oct 20
    View PubMed
  87. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
  88. Neff JL, Rangan A, Jevremovic D, Nguyen PL, Chiu A, Go RS, Chen D, Morice WG, Shi M. Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum Human Pathology. 2018; 81:96-104
  89. Abeykoon JP, Duma N, Tracy JA, Milone M, Go R. Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide. Case Rep Hematol. 2018; 2018:9615834 Epub 2018 Oct 28
    View PubMed
  90. Durani U, Shah ND, Go RS. In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample. Oncologist. 2017 Dec; 22 (12):1506-1509 Epub 2017 Sept 13
    View PubMed
  91. Goyal G, Maldonado EB, Fan TJ, Kanmanthareddy A, Silberstein PT, Go RS, Armitage JO. Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17 (12):812-818 Epub 2017 Sept 20
    View PubMed
  92. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Dingli D, Leung N, Kyle RA, Kumar SK, Gertz MA. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017 Nov; 49 (7):545-551 Epub 2017 Mar 27
    View PubMed
  93. Jawad MD, Go RS, Witzig TE, Mikhael JR, Ravindran A, Murray DL, Murrray DL. Pseudo-monoclonal gammopathy: a report of four cases. Haematologica 2017 Nov; 102 (11):e466-e469 Epub 2017 Aug 03
    View PubMed
  94. Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017 Nov; 92 (11):1146-1155 Epub 2017 Sept 08
    View PubMed
  95. Tan EM, Cawcutt KA, Zomok CD, Go RS, Sia IG. Activity of Nitazoxanide Against Viral Gastroenteritis: A Systemic Review International Journal of Travel Medicine and Global Health. 2017; 5(4):107-112.
  96. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08
    View PubMed
  97. Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. Blood. 2017 Sep 28; 130 (13):1578-1584 Epub 2017 Aug 14
    View PubMed
  98. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  99. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  100. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncol. 2017 Sep 1; 3 (9):1253-1256
    View PubMed
  101. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol. 2017 Sep; 178 (6):888-895 Epub 2017 July 12
    View PubMed
  102. Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Kumar SK. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid. 2017 Sep; 24 (3):183-188 Epub 2017 July 12
    View PubMed
  103. Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Kyle RA, Gertz MA, Vincent Rajkumar S, Kumar SK. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Am J Hematol. 2017 Sep; 92 (9):E507-E512 Epub 2017 July 19
    View PubMed
  104. Marshall AL, Durani U, Bartley A, Hagen CE, Ashrani A, Rose C, Go RS, Pruthi RK. The impact of postpartum hemorrhage on hospital length of stay and inpatient mortality: a National Inpatient Sample-based analysis. Am J Obstet Gynecol. 2017 Sep; 217 (3):344.e1-344.e6 Epub 2017 May 11
    View PubMed
  105. Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND. Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice Guidelines. Mayo Clin Proc Innov Qual Outcomes. 2017 Sep; 1 (2):161-169 Epub 2017 Aug 02
    View PubMed
  106. Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017 Sep 1; 7 (9):e600 Epub 2017 Sept 01
    View PubMed
  107. Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J 2017 Aug 25; 7 (8):e592
    View PubMed
  108. Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017 Jul; 31 (7):1562-1569 Epub 2016 Dec 01
    View PubMed
  109. Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hwa YL, Leung N, Fonder AL, Hobbs MA, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Kumar SK. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017 Jul; 92 (7):668-673 Epub 2017 May 26
    View PubMed
  110. Ravi P, Kumar S, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J. 2017 Jun 16; 7 (6):e569 Epub 2017 June 16
    View PubMed
  111. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1; 129 (22):2971-2979 Epub 2017 Mar 30
    View PubMed
  112. Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. Am J Hematol. 2017 Jun; 92 (6):549-554 Epub 2017 Apr 26
    View PubMed
  113. Huffman BM, Wiisanen J, Shi M, Go RS. Feeling run down: exercise-induced pancytopenia. Br J Haematol. 2017 Jun; 177 (5):672 Epub 2017 Apr 17
    View PubMed
  114. Muchtar E, Dean DS, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Warsame R, Gonsalves W, Kourelis TV, Go RS, Chakraborty R, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. J Intern Med. 2017 Jun; 281 (6):611-619 Epub 2017 Apr 24
    View PubMed
  115. Kourelis TV, Kyle RA, Dingli D, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Kapoor P, Go RS, Gonsalves WI, Warsame R, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Dispenzieri A. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clin Proc. 2017 Jun; 92 (6):908-917 Epub 2017 May 05
    View PubMed
  116. Durani U, Go RS. Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States. Am J Hematol 2017 Jun; 92 (6):E99-E101 Epub 2017 Apr 29
    View PubMed
  117. Durani U, Go RS. Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base. Leuk Lymphoma. 2017 May; 58 (5):1184-1189 Epub 2016 Nov 03
    View PubMed
  118. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, Zeldenrust SR, Kyle RA, Vincent Rajkumar S, Zemla T, Sloan J, Dispenzieri A. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. Am J Hematol. 2017 May; 92: (5)435-440.
    View PubMed
  119. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017 Apr 13; 129 (15):2111-2119 Epub 2017 Jan 26
    View PubMed
  120. Marshall AL, Bartley AC, Ashrani AA, Pruthi RK, Durani U, Gonsalves WI, Kapoor P, Hashmi SK, Siddiqui MA, Go RS. Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vasc Med. 2017 Apr; 22 (2):121-127 Epub 2017 Mar 20
    View PubMed
  121. Ravindran A, Go RS, Fervenza FC, Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 2017 Mar; 91 (3):691-698 Epub 2016 Dec 18
    View PubMed
  122. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar VS, Gertz MA. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid 2017 Mar; 24 (sup1):44-45
    View PubMed
  123. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid 2017 Mar; 24 (sup1):40-41
    View PubMed
  124. Go RS, Bartley AC, Crowson CS, Shah ND, Habermann EB, Holton SJ, Holmes DR 3rd. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. J Clin Oncol. 2017 Feb 20; 35: (6)598-604.
    View PubMed
  125. Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017 Feb 17; 7 (2):e528
    View PubMed
  126. Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017 Jan 5; 129 (1):82-87 Epub 2016 Oct 11
    View PubMed
  127. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3; 317 (1):48-58
    View PubMed
  128. Ravindran A, Gonsalves WI, Hashmi SK, Kapoor P, Marshall AL, Siddiqui MA, Go RS. Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? Leuk Lymphoma 2017 Jan; 58 (1):251-252 Epub 2016 June 09
    View PubMed
  129. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2017 Jan; 31 (1):92-99 Epub 2016 May 23
    View PubMed
  130. Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa L, Kourelis TV, Kyle RA, Gertz MA, Kumar SK. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017 Jan; 31 (1):130-135 Epub 2016 July 26
    View PubMed
  131. Hwa YL, Shi Q, Kumar SK, Lacy MQ, Gertz MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, Hayman SR, Gonsalves WI, Russell S, Lust JA, Lin Y, Rajkumar SV, Dispenzieri A. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. Am J Hematol. 2017 Jan; 92 (1):50-55 Epub 2016 Nov 18
    View PubMed
  132. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
    View PubMed
  133. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04
    View PubMed
  134. Jawad MD, Go RS, Reichard KK, Shi M. Increased multinucleated megakaryocytes as an isolated finding in bone marrow Am J Clin Pathol 2016;146:561-566.2016;
  135. Marshall AL, Zhang X, Lewis B, Kane S, Go RS. Sex-Based Disparities in the Use and Results of Gastrointestinal Procedures for Workup of Anemia Journal of Women’s Health, Issues & Care.2016;
  136. Jawad MD, Go RS, Reichard KK, Shi M. Increased Multinucleated Megakaryocytes as an Isolated Finding in Bone Marrow: A Rare Finding and Its Clinical Significance. Am J Clin Pathol. 2016 Nov 1; 146 (5):561-566
    View PubMed
  137. Binder M, Alkhateeb HB, Go RS. 61-Year-Old Man With Right Knee Pain and Chronic Anemia. Mayo Clin Proc. 2016 Nov; 91 (11):1640-1644 Epub 2016 Aug 04
    View PubMed
  138. Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016 Nov; 91 (11):1129-1134 Epub 2016 Aug 29
    View PubMed
  139. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016 Nov; 30 (11):2208-2213 Epub 2016 May 23
    View PubMed
  140. Paludo J, Painuly U, Kumar S, Gonsalves WI, Rajkumar V, Buadi F, Lacy MQ, Dispenzieri A, Kyle RA, Mauermann ML, McCurdy A, Dingli D, Go RS, Hayman SR, Leung N, Lust JA, Lin Y, Gertz MA, Kapoor P. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16 (11):644-654 Epub 2016 Aug 10
    View PubMed
  141. Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 2016 Oct 21; 6 (10):e486
    View PubMed
  142. Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, Hayman SR, Lin Y, Zeldenrust S, Dispenzieri A. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016 Oct; 91 (10):984-8 Epub 2016 July 14
    View PubMed
  143. Ravindran A, Grogg KL, Domaas DA, Go RS. Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity? Clin Lymphoma Myeloma Leuk. 2016 Oct; 16 (10):588-592 Epub 2016 Aug 10
    View PubMed
  144. Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clin Proc. 2016 Oct; 91: (10)1354-1361.
    View PubMed
  145. Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thome SD, Hook CC, Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016 Sep; 91 (9):1189-211 Epub 2016 Aug 03
    View PubMed
  146. Parsons BM, Landercasper J, Smith AL, Go RS, Borgert AJ, Dietrich LL. 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013. Breast Cancer Res Treat. 2016 Sep; 159 (2):315-26 Epub 2016 Aug 09
    View PubMed
  147. DeMartino E, Go RS, Vassallo R. Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung. Clin Chest Med. 2016 Sep; 37 (3):421-30 Epub 2016 June 10
    View PubMed
  148. Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016 Sep; 101 (9):1102-9 Epub 2016 June 16
    View PubMed
  149. Go RS, Al-Hamadani M, Shah ND, Crowson CS, Holton SJ, Habermann EB. Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma. Cancer. 2016 Aug 15; 122 (16):2552-9 Epub 2016 May 16
    View PubMed
  150. Shah MV, Hook CC, Call TG, Go RS. A population-based study of large granular lymphocyte leukemia. Blood Cancer J. 2016 Aug 5; 6 (8):e455 Epub 2016 Aug 05
    View PubMed
  151. Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2016 Aug; 31 (8):1284-9 Epub 2015 Nov 30
    View PubMed
  152. Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, Kourelis TV, Kyle RA, Kumar SK. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant 2016 Aug; 51 (8):1156-8 Epub 2016 Apr 11
    View PubMed
  153. Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, Lin Y, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2016 Aug; 16 (8):447-52 Epub 2016 May 05
    View PubMed
  154. Westin GF, Dias AL, Go RS. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities. Curr Hematol Malig Rep. 2016 Aug; 11 (4):271-9
    View PubMed
  155. Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016 Jul 29; 6 (7):e454 Epub 2016 July 29
    View PubMed
  156. Go RS, Swanson KM, Sangaralingham LR, Habermann EB, Shah ND. Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care. Leukemia 2016 Jun; 30 (6):1443-6 Epub 2015 Dec 09
    View PubMed
  157. Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Kyle RA, Gonsalves WI, Dispenzieri A. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. Am J Hematol. 2016 Jun; 91 (6):585-9 Epub 2016 Apr 13
    View PubMed
  158. Jawad MD, Shi M, Oliveira JL, Hoyer JD, Christopher Hook C, Go RS. Clinical course of patients with incidental finding of 20q- in the bone marrow without a morphologic evidence of myeloid neoplasm. Am J Hematol. 2016 Jun; 91 (6):556-9 Epub 2016 Apr 06
    View PubMed
  159. Go RS, Bartley AC, Al-Kali A, Shah ND, Habermann EB. Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults. Leukemia 2016 May; 30 (5):1177-80 Epub 2015 Aug 26
    View PubMed
  160. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016 May; 30 (5):1079-85 Epub 2015 Dec 16
    View PubMed
  161. Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol. 2016 May; 91 (5):473-5 Epub 2016 Apr 06
    View PubMed
  162. Sankaran J, Rodriguez V, Jacob EK, Kreuter JD, Go RS. Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience. J Pediatr Hematol Oncol. 2016 Apr; 38: (3)e120-4.
    View PubMed
  163. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016 Mar 11; 6:e401
    View PubMed
  164. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016 Mar; 30 (3):633-9 Epub 2015 Oct 21
    View PubMed
  165. Jawad MD, Go RS, Ketterling RP, Begna KH, Reichard KK, Shi M. Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report. Clin Case Rep. 2016 Mar; 4 (3):282-6 Epub 2016 Feb 08
    View PubMed
  166. Ruther NR, Mathiason MA, Wee SK, Emmel AE, Go RS. Speed of accrual into phase iii oncology trials a comparison across geographic locations American Journal Of Clinical Oncology-cancer Clinical Trials. 2015 Dec; 38: (6)575-82.
  167. Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015 Nov; 90 (11):981-5 Epub 2015 Oct 06
    View PubMed
  168. Go RS, Bottner WA, Gertz MA. Making the Case to Study the Volume-Outcome Relationship in Hematologic Cancers. Mayo Clin Proc. 2015 Oct; 90: (10)1393-9.
    View PubMed
  169. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol. 2015 Oct; 90: (10)888-91.
    View PubMed
  170. Shah MV, Go RS. Erdheim-Chester Disease. Mayo Clin Proc. 2015 Sep; 90: (9)1310.
    View PubMed
  171. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015 Sep; 90(9):790-5. Epub 2015 Jul 27.
    View PubMed
  172. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  173. Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015 Jun; 90: (6)524-8.
    View PubMed
  174. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015 May 1; 5:e310 Epub 2015 May 01
    View PubMed
  175. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015 Mar 20; 5:e296
    View PubMed
  176. Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015 Mar 1; 33 (7):740-8 Epub 2015 Jan 20
    View PubMed
  177. Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis Clinical lymphoma, myeloma & leukemia. 2015 Mar; 15: (3)177-186.e4.
    View PubMed
  178. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015 Mar; 90 (3):181-6 Epub 2015 Jan 16
    View PubMed
  179. Adegboyega TO, Landercasper J, Linebarger JH, Johnson JM, Andersen JJ, Dietrich LL, Driscoll CD, Raghavendra M, Madadi AR, Al-Hamadani M, Vang CA, Marcou KA, Hudak J, Go RS. Institutional review of compliance with NCCN guidelines for breast cancer: Lessons learned from real-time multidimensional synoptic reporting. J. Natl. Compr. Cancer Netw. 2015; 13(2):177-83.
  180. Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02.
    View PubMed
  181. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, Kumar SK. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014 Aug 7; 124 (6):907-12 Epub 2014 June 23
    View PubMed
  182. Langford AT, Resnicow K, Dimond EP, Denicoff AM, Germain DS, McCaskill-Stevens W, Enos RA, Carrigan A, Wilkinson K, Go RS. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. Cancer. 2014 Mar 15; 120(6):877-84. Epub 2013 Dec 10.
    View PubMed
  183. Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2014 Mar; 89 (3):302-5 Epub 2014 Feb 18
    View PubMed
  184. Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014; 89(8):825-30.
    View PubMed
  185. Shah MV, Go RS. EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis. Blood. 2014; 124(22):3329.
    View PubMed
  186. Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM. ECOG phase II trial of graded-dose peginterferon alpha-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 1; 19(23):6597-604. Epub 2013 Oct 11.
    View PubMed
  187. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkaer K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Moller MB, Young KH, Tzankov A. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013 Nov; 66(11):956-61. Epub 2013 Jun 17
    View PubMed
  188. Xu-Monette ZY, Moller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40. Epub 2013 Aug 27.
    View PubMed
  189. Sharma UM, Schroeder JE, Al-Hamadani M, Mathiason MA, Meyer CM, Frisby KA, Meyer LA, Sieber DL, Go RS. An exploratory study of the use of advance directives by US oncologists. WMJ. 2013 Aug; 112(4):158-61.
    View PubMed
  190. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Moller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40. Epub 2013 Mar 20
    View PubMed
  191. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Moller MB, Medeiros LJ, Young KH. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Blood. 2013 May 16; 121(20):4021-31; quiz 4250. Epub 2013 Feb 28
    View PubMed
  192. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Moller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 4; 121(14):2715-24. Epub 2013 Jan 23
    View PubMed
  193. Zaren HA, Nair S, Go RS, Enos RA, Lanier KS, Thompson MA, Zhao J, Fleming DL, Leighton JC, Gribbin TE, Bryant DM, Carrigan A, Corpening JC, Csapo KA, Dimond EP, Ellison C, Gonzalez MM, Harr JL, Wilkinson K, Denicoff AM. Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment. J Oncol Pract. 2013 Mar; 9(2):e55-61.
    View PubMed
  194. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Moller MB, Wu L, Medeiros LJ, Young KH. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98 (2):255-63 Epub 2012 Aug 28
    View PubMed
  195. Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, Gascoyne RD, Kolesar J, Kahl BS, Horning S. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). J Hematol Oncol. 2013; 6:46. Epub 2013 Jul 05.
    View PubMed
  196. *Sharma UM, Meyer CM, Mathiason MA, Schroeder JE, Sieber DL, Frisby KA, Meyer LA, Pingali SR, Emmel AE, Go RS. Nature and outcome of clinical trials conducted by the Eastern Cooperative Group: a 30-year study from 1977-2006. Forthcoming. 2013; In press).
  197. Averbook BJ, Lee SJ, Delman K, Gow KW, Zager JS, Sondak VK, Messina J, Sabel M, Pittelkow M, Ecker PM, Markovic SN, Swetter SM, Leachman S, Testori A, Curiel-Lewandrowski C, Go RS, Jukic DM, Kirkwood JM. Pediatric melanoma and atypical melanocytic neoplasms in children: analysis of an international registry. Cancer (. 2013; In press).
  198. Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM. Peg-interferon α-2b suppresses basic fibroblast growth factor in patients with metastatic melanoma over-expressing basic fibroblast growth factor: an Eastern Cooperative Oncology Group study E2602. Forthcoming. 2013; Accepted).
  199. Langford AT, Resnicow K, Dimond EP, St Germain D, McCaskill-Stevens W, Enos RA, Carrigan A, Wilkinson K, Go RS. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. Forthcoming. 2013; Accepted).
  200. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Fan L, Visco C, Dybkær K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Wu L, Zhao X, Go RS, Wang SA, Bueso-Ramos CE, Li Y, Piris MA, Medeiros LJ, Young. KHMDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with Rituximab-CHOP immunochemotherapy. Forthcoming. 2013; Accepted).
  201. Averbook BJ, Lee SJ, Delman KA, Gow KW, Zager JS, Sondak VK, Messina JL, Sabel MS, Pittelkow MR, Ecker PM, Markovic SN, Swetter SM, Leachman SA, Testori A, Curiel-Lewandrowski C, Go RS, Jukic DM, Kirkwood JM. Pediatric melanoma: Analysis of an international registry. Cancer. 2013; 119(22):4012-9.
    View PubMed
  202. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Moller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 8; 120(19):3986-96. Epub 2012 Sep 05.
    View PubMed
  203. Conrad AL, Gundrum JD, McHugh VL, Go RS. Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma. J Oncol Pract. 2012 Nov; 8(6):336-40. Epub 2012 Sep 18.
    View PubMed
  204. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Moller MB. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 Oct 1; 30(28):3460-7. Epub 2012 Jun 4
    View PubMed
  205. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkaer K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Moller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Sep; 26 (9):2103-13 Epub 2012 Mar 22
    View PubMed
  206. *Gundrum JD, Go RS. Cancer in the oldest old: current statistics and projection. J Ger Oncol. 2012; 3:299-306.
  207. Conrad AL, Gundrum JD, McHugh VL, Go RS. Utility of routine cardiac ejection fraction measurement prior to anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma. J Oncol Pract 8;336-340. 2012.
  208. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, Diaz Uriarte R, Rodriguez ME, Saez A, Montalban C, Gomez G, Pisano DG, Garcia JF, Conde E, Gonzalez-Barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dunphy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-Monette Z, Young KH, Piris MA. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011 Jul 28; 118(4):1034-40. Epub 2011 Jun 1
    View PubMed
  209. Zurbriggen LD, Gundrum JD, Policepatil SM, Pingali SR, Zeng GG, Go RS. Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. Am J Hematol. 2011 Jul; 86(7):622-4.
    View PubMed
  210. Policepatil SM, Go RS, Zeng GG. Floral variant of follicular lymphoma. Am J Hematol. 2011 Jun; 86(6):503. Epub 2011 Jan 26.
    View PubMed
  211. Poonacha TK, Go RS. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol. 2011 Jan 10; 29(2):186-91. Epub 2010 Dec 13.
    View PubMed
  212. *Zurbriggen LD, McHugh VL, Gundrum JD, Go RS. Nature and extent of financial conflicts of interest among planning committee members, speakers, and abstract presenters at the American Association for Cancer Research Annual Meetings. Gundersen Lutheran Med J. 2011; 7:15-18.
  213. Conrad AL, Go RS. Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma. Eur J Haematol. 2009 Dec 1; 83(6):603-5. Epub 2009 Aug 04.
    View PubMed
  214. Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009 Nov 1; 27(31):5227-32. Epub 2009 Sep 21.
    View PubMed
  215. Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma. 2009 Oct; 9(5):E25-9.
    View PubMed
  216. Hoeg RT, Lee JA, Mathiason MA, Rokkones K, Serck SL, Crampton KL, Emmel AE, Severson EA, Go RS. Publication outcomes of phase II oncology clinical trials. Am J Clin Oncol. 2009 Jun; 32(3):253-7.
    View PubMed
  217. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009 Feb; 144(3):409-15. Epub 2008 Nov 11.
    View PubMed
  218. Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, Bottner WA, Cole CE, Farnen JP, Frisby KA. Circulating endothelial cells in patients with chronic lymphocytic leukemia. Ann Hematol. 2008 May; 87(5):369-73. Epub 2008 Jan 12.
    View PubMed
  219. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2; 371(9610):395-403.
    View PubMed
  220. Go RS, Hammes BA, Lee JA, Mathiason MA. Advance directives among health care professionals at a community-based cancer center. Mayo Clin Proc. 2007 Dec; 82(12):1487-90.
    View PubMed
  221. *Bowman J, Keller JK, Lee JA, Frisby KA, Mathiason MA, Meyer CM, Meyer LA, Wright LJ, Go RS. Cancer clinical trials available in the community setting: A five-year analysis from 1999-2004. Community Oncol. 2007; 4:695-700.
  222. Reed BW, Go RS. Pseudothrombocytopenia associated with multiple myeloma. Mayo Clin Proc. 2006 Jul; 81(7):869.
    View PubMed
  223. Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, Walther SM, Schroeder JE, Meyer LA, Umberger KE. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006 Jan 15; 106(2):426-33.
    View PubMed
  224. Brasic GM, Meyer LA, Bottner WA, Go RS. Cyclic thrombocytopenia: an important but often neglected differential diagnosis in patients with suspected idiopathic immune thrombocytopenia. Gundersen Lutheran Med J. 2006; 4:26-28.
  225. Johnston KL, Farnen JP, Manske BR, Go RS. Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors. Haematologica. 2005 Dec; 90(12 Suppl):EIM03.
    View PubMed
  226. Horstman AL, Serck SL, Go RS. Macrocytosis associated with monoclonal gammopathy. Eur J Haematol. 2005 Aug; 75(2):146-9.
    View PubMed
  227. Go RS. Idiopathic cyclic thrombocytopenia. Blood Rev. 2005 Jan; 19(1):53-9.
    View PubMed
  228. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004 Sep 15; 101(6):1404-13.
    View PubMed
  229. Horstman AL, Go RS, Bottner WA. Cranial vault lymphoma. Haematologica. 2004 Apr; 89(4):EIM06.
    View PubMed
  230. Williams E, Smart SC, Go RS. Catastrophic thromboembolism in a patient with acute lymphoblastic leukemia and hypereosinophilia. Haematologica. 2004 Apr; 89(4):EIM01.
    View PubMed
  231. Wenburg JJ, Go RS. EDTA-dependent lymphocyte clumping. Haematologica. 2003 Aug; 88(8):EIM09.
    View PubMed
  232. Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte lukemia. Semin Hematol. 2003 Jul; 40(3):196-200.
    View PubMed
  233. Go RS, Gazelka H, Hogan JD, Wester SM. Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine. Ann Hematol. 2003 Apr; 82(4):247-50. Epub 2003 Mar 18.
    View PubMed
  234. Go RS, Johnston KL. Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome. Eur J Haematol. 2003 Apr; 70(4):246-8.
    View PubMed
  235. Go RS, Ritman EL, Owen WG. Angiogenesis in rat aortic rings stimulated by very low concentrations of serum and plasma. Angiogenesis. 2003; 6 (1):25-9
    View PubMed
  236. Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15; 98 (2):483-5
    View PubMed
  237. Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000 Nov 15; 96(10):3644-6.
    View PubMed
  238. Shoho AR, Go RS, Tefferi A. 22-year-old woman with severe microcytic anemia. Mayo Clin Proc. 2000 Aug; 75 (8):861-4
    View PubMed
  239. Go RS, Klee GG, Richardson RL. Use of pleural fluid prostate specific antigen in the diagnosis of malignant effusion from metastatic prostate cancer. J Urol. 2000 Aug; 164(2):459.
    View PubMed
  240. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc. 2000 Jan; 75(1):83-5.
    View PubMed
  241. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999 Jan; 17: (1)409-22.
    View PubMed
  242. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology. 1998 Dec; 51 (6):1718-20
    View PubMed
  243. Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid. 1995 Oct; 5(5):403-5.
    View PubMed